KROS

Keros Therapeutics Stock Analysis

AI Rating

Good
  • Quality5/10
  • Growth↑ 8/10
  • Value↑ 5/10
Keros Therapeutics sales and earnings growth
KROS Growth
Good
  • Revenue Y/Y↑ 6774.96%
  • EPS Y/Y↑ 146.80%
  • FCF Y/Y↑ 165.08%
Keros Therapeutics gross and profit margin trends
KROS Profitability
Great
  • Gross margin ↑ 100.00%
  • EPS margin↑ 35.70%
  • ROIC 5Y↑ -332.63%
Keros Therapeutics net debt vs free cash flow
KROS Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Keros Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗